ong term effects of DPP-IV inhibitor treatment on the secretion and action of the incretin hormones in patients with type 2 diabetes
- Conditions
- Type 2 diabetes diagnosed according to the criteria from WHO
- Registration Number
- EUCTR2006-002950-32-DK
- Lead Sponsor
- Gentofte University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Recruiting
- Sex
- All
- Target Recruitment
- 48
•Type 2 diabetes diagnosed according to and in accordance with the WHO criteria
•Metformin treatment of = 1 gram
•7,0 % = HbA1c = 10%
•Age > 18
•BMI = 25 kg/m2
•Informed consent
•Contraception, if appropriate
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
•Proliferating retinopathy
•Uremia, end stage renal disease, diabetic nephropathy or any other cause of impaired renal function with s-creatinine > 130 µM and/or albuminuria (>300 mg/day)
•Liver disease with ALAT and/or ASAT > 2 x normal value
•Complicated coronary artery disease, NYHA group III and IV
•Positive screening for islet cell auto antibodies and/or GAD-65 auto antibodies
•Occurrence of type 1 diabetes in first degree relatives
•Anaemia
•Pregnancy and/or breast feeding
•Treatment with medication affecting insulin secretion
•non-compliance
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method